Cargando…

Signaling protein signature predicts clinical outcome of non-small-cell lung cancer

BACKGROUND: Non-small-cell lung cancer (NSCLC) is characterized by abnormalities of numerous signaling proteins that play pivotal roles in cancer development and progression. Many of these proteins have been reported to be correlated with clinical outcomes of NSCLC. However, none of them could provi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Bao-Feng, Yang, Fan, Ying, Xiao-Min, Gong, Lin, Hu, Shuo-Feng, Zhao, Qing, Liao, Yi-Da, Chen, Ke-Zhong, Li, Teng, Tai, Yan-Hong, Cao, Yuan, Li, Xiao, Huang, Yan, Zhan, Xiao-Yan, Qin, Xuan-He, Wu, Jin, Chen, Shuai, Guo, Sai-Sai, Zhang, Yu-Cheng, Chen, Jing, Shen, Dan-Hua, Sun, Kun-Kun, Chen, Lu, Li, Wei-Hua, Li, Ai-Ling, Wang, Na, Xia, Qing, Wang, Jun, Zhou, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840771/
https://www.ncbi.nlm.nih.gov/pubmed/29510676
http://dx.doi.org/10.1186/s12885-018-4104-4
Descripción
Sumario:BACKGROUND: Non-small-cell lung cancer (NSCLC) is characterized by abnormalities of numerous signaling proteins that play pivotal roles in cancer development and progression. Many of these proteins have been reported to be correlated with clinical outcomes of NSCLC. However, none of them could provide adequate accuracy of prognosis prediction in clinical application. METHODS: A total of 384 resected NSCLC specimens from two hospitals in Beijing (BJ) and Chongqing (CQ) were collected. Using immunohistochemistry (IHC) staining on stored formalin-fixed paraffin-embedded (FFPE) surgical samples, we examined the expression levels of 75 critical proteins on BJ samples. Random forest algorithm (RFA) and support vector machines (SVM) computation were applied to identify protein signatures on 2/3 randomly assigned BJ samples. The identified signatures were tested on the remaining BJ samples, and were further validated with CQ independent cohort. RESULTS: A 6-protein signature for adenocarcinoma (ADC) and a 5-protein signature for squamous cell carcinoma (SCC) were identified from training sets and tested in testing sets. In independent validation with CQ cohort, patients can also be divided into high- and low-risk groups with significantly different median overall survivals by Kaplan-Meier analysis, both in ADC (31 months vs. 87 months, HR 2.81; P <  0.001) and SCC patients (27 months vs. not reached, HR 9.97; P <  0.001). Cox regression analysis showed that both signatures are independent prognostic indicators and outperformed TNM staging (ADC: adjusted HR 3.07 vs. 2.43, SCC: adjusted HR 7.84 vs. 2.24). Particularly, we found that only the ADC patients in high-risk group significantly benefited from adjuvant chemotherapy (P = 0.018). CONCLUSIONS: Both ADC and SCC protein signatures could effectively stratify the prognosis of NSCLC patients, and may support patient selection for adjuvant chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4104-4) contains supplementary material, which is available to authorized users.